

Through Email/ Fax/ Courier

FKOL/SE

August 8, 2013

National Stock Exchange of India Ltd. (NSE)

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East)
Mumbai-400 051
Fax : 022 – 26598237/ 38

Bombay Stock Exchange Ltd. (BSE)

Corporate Relationship Department
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400 001
Fax: 022 – 22723121

Fresenius Kabi Oncology Limited

Echelon Institutional Area, Plot No. 11,
Sector 32, Gurgaon - 122 001, Haryana, India
T +91-124-4885000, +91-124-3325000
F +91-124-4885003
www.fresenius-kabi-oncology.com

Sub: Approval of Unaudited Financial Results for the 1st Quarter ended June 30, 2013

Ref: NSE Symbol: FKONCO, BSE Scrip Code: 532545

Dear Sirs,

Please be informed that the Board of Directors of the Company, at its meeting concluded at 2:33 P.M., has approved and taken on record the unaudited Financial Results of the Company for the 1st Quarter ended June 30, 2013, along with the Limited Review Report of the Statutory Auditors thereon, which are being faxed herewith and separately being e-mailed and couriered.

The above is for your information and record and in compliance of Clause 41 of the Listing Agreement with the Stock Exchanges.

Thanking you,

Yours sincerely,
For **Fresenius Kabi Oncology Limited**



Nikhil Kulshreshtha
Company Secretary & Head – Legal

Encl: a/a

Fresenius Kabi Oncology Limited

Regd. Office : B- 310, Som Datt Chambers - I, Bhikaji Cama Place, New Delhi - 110066

Unaudited Financial Results for the Quarter Ended 30th June 2013

(Rs. In Laacs)

Particulars	Unaudited for the Quarter ended June 2013	Audited for the Quarter ended March 2013	Unaudited for the Quarter ended June 2012	Audited for the Year ended 31st March 13
1 Income from operations				
a. Net Sales/Income from Operations (Net of Excise duty)	8,094.61	7,054.44	12,406.46	49,624.62
b. Other operating income	4,592.01	2,269.06	942.80	10,005.37
Total Income from operations (net)	12,686.62	9,323.50	13,349.26	59,629.99
2 Expenditure:				
a. (Increase)/decrease in stock in trade & work in progress	114.77	(3,451.95)	(1,125.99)	(3,101.74)
b. Consumption of raw material	3,558.72	5,154.54	5,744.12	19,173.52
c. Purchase of trading goods	24.40	147.62	78.52	424.55
d. Employee cost	1,521.41	1,740.51	1,785.30	7,032.04
e. Depreciation	690.77	653.00	616.21	2,578.62
f. Research & Development	3,783.95	926.38	1,738.65	9,503.33
g. Other expenditure	2,835.24	3,671.18	2,895.38	12,298.21
h. Total	12,529.26	8,841.28	11,732.19	47,908.53
3 Profit from operations before other income, Interest and exceptional items (1-2)	157.36	482.22	1,617.07	11,721.46
4 Other Income	85.53	81.98	47.86	180.10
5 Profit before interest and exceptional items (3+4)	242.89	564.20	1,664.93	11,901.56
6 Finance Charges	(467.67)	(206.56)	(10.24)	(260.30)
7 Profit after interest but before exceptional items (5-6)	710.56	770.76	1,675.17	12,161.86
8 Exceptional Items	-	-	-	-
9 Profit (+)/Loss (-) from ordinary activities before tax (7+8)	710.56	770.76	1,675.17	12,161.86
10 Provision for taxation:				
-Current tax	142.11	172.78	335.03	2,451.00
-Deferred tax	88.44	693.15	36.57	971.35
11 Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)	480.01	(95.17)	1,303.57	8,739.51
12 Extraordinary item (After tax)	-	(680.64)	-	(680.64)
13 Net Profit(+)/Loss(-) for the period (11+12)	480.01	(775.81)	1,303.57	8,058.87
14 Paid-up equity share capital (face value of Re 1 Each)	1,582.28	1,582.28	1,582.28	1,582.28
15 Reserves excluding revaluation reserves				65,735.77
16 Basic EPS (Excluding Extraordinary item) (in Rs not annualised)	0.30	(0.06)	0.82	5.52
17 Diluted EPS (Excluding Extraordinary item) (in Rs not annualised)	0.30	(0.06)	0.82	5.52
18 Basic EPS (Including Extraordinary items) (in Rs not annualised)	0.30	(0.49)	0.82	5.09
19 Diluted EPS (Including Extraordinary item) (in Rs not annualised)	0.30	(0.49)	0.82	5.09

RB

Select Information for the Quarter Ended 30th June 2013

S.No	Particulars	Unaudited for the Quarter ended June 2013	Audited for the Quarter ended March 2013	Unaudited for the Quarter ended June 2012	Audited for the Year ended 31st March' 13
A	Particulars of Shareholding				
1	Public Shareholding:				
	-Number of shares	30063255	30063255	15822766	30063255
	-Percentage of Shareholding	19	19	10	19
2	Promoter & Promoter Group Shareholding				
	a) Pledged/Encumbered				
	-Number of shares	Nil	Nil	Nil	Nil
	Percentage of Share (As % of total shareholding of promoter & promoter group)	Nil	Nil	Nil	Nil
	Percentage of Share (As % of total share capital of the Company)	Nil	Nil	Nil	Nil
	b) Non Encumbered				
	-Number of shares	128164400	128164400	142404889	128164400
	Percentage of Share (As % of total shareholding of promoter & promoter group)	100	100	100	100
	Percentage of Share (As % of total share capital of the Company)	81	81	90	81
B	Investors Complaints				
	Pending at the beginning of the quarter	0			
	Received during the Quarter	9			
	Disposed of during the quarter	9			
	Remaining at the end of the quarter	0			



Unaudited Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2013

					(Rs. In Lacs)
Particulars	Unaudited for the Quarter ended June 2013	Audited for the Quarter ended March 2013	Unaudited for the Quarter ended June 2012	Audited for the Year ended 31st March 13	
1 Segment Revenue					
A. Formulation	8,357.15	7,508.44	10,790.11	45,224.85	
B. Bulk Drug	787.89	478.43	6,085.09	19,062.44	
C. R&D Service	4,317.34	1,723.40	675.89	8,312.74	
Total Income from Operations	13,462.38	9,710.27	17,551.09	72,600.03	
Less : Inter Segment Revenue	775.76	386.77	4,201.83	12,970.04	
Net Income from Operation	12,686.62	9,323.50	13,349.26	59,629.99	
2 Segment Results (Profit (+) /Loss (-) before tax, interest and unallocable overheads)					
A. Formulation	4,168.04	2,469.51	2,577.52	17,702.63	
B. Bulk Drug	(3,003.63)	(2,474.97)	464.00	(1,516.12)	
C. R&D Income	454.22	167.60	60.24	569.98	
Total	1,618.63	162.14	3,101.76	16,756.49	
Less : 1) Finance Charges (Unallocated)	229.84	(1,028.70)	148.45	(38.87)	
2) Unallocable Expenditure net off unallocable income	678.23	420.08	1,278.13	4,633.50	
Total profit before tax	710.56	770.76	1,675.18	12,161.86	
3 Capital Employed (Segment Assets less Segment Liabilities)					
A. Formulation	50,133.21	50,950.35	49,199.71	50,950.35	
B. Bulk Drug	17,856.93	19,876.45	21,692.02	19,876.45	
C. R&D Service	7,537.54	4,009.98	1,511.84	4,009.98	
D. Unallocable Capital Employed	(7,729.62)	(7,518.73)	(11,853.15)	(7,518.73)	
Total Capital Employed	67,798.06	67,318.05	60,550.42	67,318.05	

Notes on results for the quarter ended 30th June 2013

- 1 Net Sales for the current quarter is Lesser by 34.75 % than corresponding previous year quarter.
- 2 Fall of revenue and loss in bulk drug segment are attributed to temporary suspension of production at bulk drug unit at kalyani for technical upgradation.
- 3 Exchange gain for the current quarter Rs. 598.03 lacs is netted against finance charges.
- 4 The figures of earlier periods have been regrouped and reclassified wherever necessary in line with current year grouping.
- 5 The above results have been reviewed by statutory auditors, audit committee and approved by the Board of Directors in the meeting held on 8th Aug. 2013

Gurgaon: 8th August 2013

By Order of the Board
For Fresenius Kabi Oncology Limited


Rakesh Bhargava
Chairman

LIMITED REVIEW REPORT OF THE AUDITOR

To

The Board of Directors,
Fresenius Kabi Oncology Limited

We have reviewed the accompanying statement of unaudited financial results of Fresenius Kabi Oncology Limited for the quarter ended 30th June, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors during meeting dated 8th August, 2013. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement

For G. Basu & Co
Chartered Accountants
Firm Registration Number: 301174E

Place : Gurgaon
Date : 8th August, 2013



S. Lahiri
Partner

M. No-51717